Dr. Sherene Loi is a medical oncologist who specializes in treating breast cancer. In addition to treating patients, particularly patients diagnosed with HER2-positive breast cancer, she also leads the Translation Breast Cancer Genomics and Therapeutics Laboratory at the Peter MacCallum Cancer Centre in Melbourne, Australia, where she is a professor. Much of her clinical research focuses on investigating new treatments, such as immunotherapy, especially for breast cancers that have become resistant to standard treatments. Listen to the podcast to hear Dr. Loi explain: results from the PANACEA trial, which looked at using the immunotherapy medicine Keytruda (chemical name: pembrolizumab) along with Herceptin to treat Herceptin-resistant, HER2-positive, advanced-stage breast cancer that had high levels of PDL-1, a biomarker that indicates that Keytruda will be effective how an immunotherapy medicine like Keytruda works what tumor-infiltrating lymphocytes (TILs) are and why cancer tumors with high numbers of TILs seem to respond better to immunotherapy side effects of immunotherapy medicines

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related